|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
EUCTR |
|
Last refreshed on:
|
4 April 2022 |
|
Main ID: |
EUCTR2009-016654-41-FR |
|
Date of registration:
|
04/01/2010 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
A Phase 2 Study of Ataluren (PTC124) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia
|
|
Scientific title:
|
A Phase 2 Study of Ataluren (PTC124) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia |
|
Date of first enrolment:
|
02/03/2010 |
|
Target sample size:
|
18 |
|
Recruitment status: |
Not Recruiting |
|
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016654-41 |
|
Study type:
|
Interventional clinical trial of medicinal product |
|
Study design:
|
Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product:
Placebo:
Other:
|
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
|
Countries of recruitment
|
|
Belgium
|
France
|
Italy
|
United Kingdom
| | | | |
|
Contacts
|
|
Name:
|
|
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
|
|
Name:
|
|
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
1. Evidence of signed and dated informed consent document(s) indicating that the subject (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study. Note: If the study candidate is considered a child or is unable to give consent under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written assent. The rules of the responsible Institutional Review Board/Independent Ethic Committee (IRB/IEC) regarding whether one or both parents must provide consent and the appropriate ages for obtaining consent and assent from the subject should be followed.
2. Age =2 years at the start of study drug.
3. Phenotypic evidence of MMA based on the presence of characteristic clinical symptoms or signs and an elevated plasma MMacid level as specified in Table 1 of the protocol.
4. Documentation of the presence of a nonsense mutation in at least 1 allele of the MUT or MMAA (cblA) or MMAB (cblB) gene.
5. Verification that a blood sample has been drawn for sequencing of the relevant gene at a certified laboratory. Note: A subject who has written documentation of a nonsense mutation as the cause for MMA need not wait for confirmatory results to start ataluren as long as the confirmatory genotyping blood sample has been drawn.
6. Confirmed screening laboratory values within the central laboratory ranges specified in Table 1 of the protocol. Note: Confirmation should be performed for out-of-range values to determine if the abnormality is real or artifactual. Values used to establish eligibility should be obtained within the screening period, and should generally be the most recent measurement.
7. Willingness, if not surgically sterile, to abstain from sexual intercourse or employ a barrier or medical method of contraception during ataluren administration and follow-up periods.
8. Willingness and ability to comply with scheduled visits, drug administration plan, study procedures, and study restrictions. Note: Psychological, social, familial, or geographical factors that might preclude adequate study participation should be considered.
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion criteria:
1. Known hypersensitivity to any of the ingredients or excipients of the study drug
(polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, colloidal silica, or magnesium stearate).
2. Any change (initiation, change in type of drug, dose modifications, schedule modifications, interruption, discontinuation or reinitiation) in chronic treatment for MMA (eg, cobalamin, L-carnitine, antibiotics for gut flora) within 2 months prior to start of Screening laboratory assessments.
3. Any change in prescribed diet, protein intake, or caloric intake within 2 months prior to start of Screening laboratory assessments.
4. Episode of metabolic decompensation within 1 month prior to start of Screening laboratory assessments.
5. Exposure to another investigational drug within 1 month prior to start of study drug.
6. Ongoing dialysis for renal dysfunction.
7. History of any form of organ transplantation or expectation that the patient may undergo organ transplantation during the planned study period.
8. Ongoing participation in any other therapeutic clinical trials.
9. Prior or ongoing medical condition (eg, concomitant illness, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator’s opinion, could adversely affect the safety of the subject, makes it unlikely that the course of study drug administration or follow-up would be completed, or could impair the assessment of study results.
Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
|
|
Health Condition(s) or Problem(s) studied
|
Nonsense Mutation Methylmalonic Acidemia
MedDRA version: 12.1
Level: LLT
Classification code 10064180
Term: Blood methylmalonic acid increased
|
|
Intervention(s)
|
Product Name: Ataluren 125mg
Product Code: PTC124
Pharmaceutical Form: Powder for oral suspension
INN or Proposed INN: ataluren
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Other descriptive name: PTC-0161480; PTC-124; Compound 1a; RPS 2505; PTC-C124; 291844
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Product Name: Ataluren 250mg
Product Code: PTC124
Pharmaceutical Form: Powder for oral suspension
INN or Proposed INN: ataluren
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Other descriptive name: PTC-0161480; PTC-124; Compound 1a; RPS 2505; PTC-C124; 291844
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-
Product Name: Ataluren 1000mg
Product Code: PTC124
Pharmaceutical Form: Powder for oral suspension
INN or Proposed INN: ataluren
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Other descriptive name: PTC-0161480; PTC-124; Compound 1a; RPS 2505; PTC-C124; 291844
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1000-
|
|
Primary Outcome(s)
|
Secondary Objective: • To determine whether treatment with ataluren reduces urinary MMacid levels
• To explore the effect of ataluren on urinary levels of methylcitrate, on plasma levels of propionylcarnitine, on erythrocyte OLCFAs, and on urinary urea:MMacid ratio
• To explore the effect of ataluren on enzyme activity in cultured fibroblast cells and in lymphocytes from patients with nmMMA
• To explore the reliability of developmental/cognitive tests and a dystonia rating scale in patients with nmMMA
• To document the occurrence of any metabolic decompensation episodes
• To characterize the safety profile of ataluren in subjects with nmMMA
• To determine compliance with ataluren administration
• To evaluate the PK profile of ataluren in subjects with nmMMA (including those with renal dysfunction)
|
|
Main Objective: To determine whether treatment with ataluren reduces plasma MMacid levels
|
|
Primary end point(s): Change in plasma MMacid levels during 4 weeks of ataluren treatment
|
|
Secondary ID(s)
|
|
PTC124-GD-012-MMA
|
|
Source(s) of Monetary Support
|
|
Ethics review
|
Status: Approved
Approval date: 02/03/2010
Contact:
|
|